Page 3 - Ancer Prostate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

When informed about treatment options, most men with low-risk prostate cancer chose active surveillance instead of active therapy in a recent Italy-based analysis.

Preliminary real-world audit data show reduced A1c among men who received testosterone replacement therapy over a 2-year period.

Continuing ADT beyond 6 months does not improve outcomes in men with high-risk localized prostate cancer also receiving brachytherapy and external beam radiation therapy, new research suggests.

A new study identifies three factors associated with PSA failure in men with nonmetastatic unfavorable-risk prostate cancer, revealing who may benefit from treatment escalation.

The use of doublet therapy has increased survival by 6 months, on average, in men with de novo metastatic castration-sensitive prostate cancer, according to Swedish registry data.